The Association Between STX1B Polymorphisms and Treatment Response in Patients With Epilepsy
Background: Epilepsy is a debilitating brain disease with complex inheritance and frequent treatment resistance. However, the role of STX1B single nucleotide polymorphisms (SNPs) in epilepsy treatment remains unknown. Objective: This study aimed to explore the genetic association of STX1B SNPs with...
Saved in:
Published in | Frontiers in pharmacology Vol. 12; p. 701575 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
09.07.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background:
Epilepsy is a debilitating brain disease with complex inheritance and frequent treatment resistance. However, the role of
STX1B
single nucleotide polymorphisms (SNPs) in epilepsy treatment remains unknown.
Objective:
This study aimed to explore the genetic association of
STX1B
SNPs with treatment response in patients with epilepsy in a Han Chinese population.
Methods:
We first examined the associations between
STX1B
SNPs and epilepsy in 1000 Han Chinese and the associations between
STX1B
SNPs and drug-resistant epilepsy in 450 subjects. Expression quantitative trait loci analysis was then conducted using 16 drug-resistant epileptic brain tissue samples and results from the BrainCloud database (
http://eqtl.brainseq.org
).
Results:
The allelic frequencies of rs140820592 were different between the epilepsy and control groups (
p
= 0.002) after Bonferroni correction. The rs140820592 was associated with significantly lower epilepsy risk among 1,000 subjects in the dominant model after adjusting for gender and age and Bonferroni correction (OR = 0.542, 95%CI = 0.358–0.819,
p
= 0.004). The rs140820592 also conferred significantly lower risk of drug-resistant epilepsy among 450 subjects using the same dominant model after adjusting for gender and age and Bonferroni correction (OR = 0.260, 95%CI = 0.103–0.653,
p
= 0.004). Expression quantitative trait loci analysis revealed that rs140820592 was associated with
STX1B
expression level in drug-resistant epileptic brain tissues (
p
= 0.012), and this result was further verified in the BrainCloud database (
http://eqtl.brainseq.org
) (
p
= 2.3214 × 10
–5
).
Conclusion:
The
STX1B
rs140820592 may influence the risks of epilepsy and drug-resistant epilepsy by regulating
STX1B
expression in brain tissues. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Pharmacogenetics and Pharmacogenomics, a section of the journal Frontiers in Pharmacology Stanley Hooker, City of Hope National Medical Center, United States Reviewed by: Yanfei Zhang, Geisinger Health System, United States Edited by: Youssef Daali, Geneva University Hospitals (HUG), Switzerland |
ISSN: | 1663-9812 1663-9812 |
DOI: | 10.3389/fphar.2021.701575 |